Show
Sort by
-
Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BMF AML Study Group and EWOG-MDS
-
- Journal Article
- A1
- open access
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL : the HOVON-100 trial
-
- Journal Article
- A1
- open access
CircRNAs dysregulated in juvenile myelomonocytic leukemia : CircMCTP1 stands out
-
Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes
-
- Journal Article
- A1
- open access
Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome
-
Association of unbalanced translocation der(1;7) with germline GATA2 mutations
-
- Journal Article
- A1
- open access
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia
-
- Journal Article
- A1
- open access
Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency
-
Long non-coding RNAs as novel therapeutic targets in juvenile myelomonocytic leukemia : proof of concept study
-
Response-guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AML-01
-
RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
-
The genetic basis and cell of origin of mixed phenotype acute leukaemia
-
Leukaemic stem cell load at diagnosis predicts the development of relapse in young acute myeloid leukaemia patients
-
Recurrently affected genes in juvenile myelomonocytic leukaemia
-
Genomic landscape of pediatric mixed phenotype acute leukemia
-
Comparison between FLT3-ITD measurements based on RNA and DNA of childhood myeloid leukemia samples
-
LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19
-
The relevance of stem cell load at diagnosis for the development of relapse in pediatric acute myeloid leukemia
-
Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics
-
Mutational spectrum of juvenile myelomonocytic leukemia